The FDA has approved an HIV dual therapy developed by GSK’s specialist joint venture, ViiV Healthcare, a convenient combination that will compete with Gilead's nearly-approved three-drug regimen.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback